Enablex medicine is indicated for the treatment of symptoms of overactive bladder. It helps in Urinary incontinence and other problems related to it. This medicine is available in the form of an extended-release tablet and in a dosage of 600 mg. It is composed of Darifenacin hydrobromide as the main active ingredient. This active component belongs to a class of drugs known as antimuscarinics. This medicine is manufactured by Allergan Pharmaceuticals, a trusted manufacturing company.
Active Ingredient: Darifenacin hydrobromide is the main active ingredient in the given medicine. This active component is the hydrobromide salt of darifenacin. This medication is responsible for bladder muscle contractions and used in the management of urinary incontinence. It plays the role of a muscarinic antagonist.
Indications: This mentioned medicine Enablex is used to reduce muscle spasms of the bladder and urinary tract. This pill is used to treat symptoms of overactive bladder like frequent or urgent urination, and incontinence i.e. urine leakage. This medicine is a muscarinic antagonist approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Action Mechanism: The action mechanism of the medicine depends on the active ingredient, Darifenacin. It works by giving the people better control over bladder muscle contractions. Urinary incontinence can occur when muscles that control the bladder become more active and contract involuntarily. The pill relaxes the bladder muscles to prevent urgent, frequent or uncontrolled urination and reduces the number of bladder contractions. So, the frequency of urination decreases.
Dosages: This mentioned medicine Enablex belongs to a class of drugs known as antimuscarinics. A dosage available as follows:
- 7.5 mg: This extended-release tablet must be taken once a day as mentioned in the prescription by the doctor
Note: This medicine should be administered with caution to people with bladder outflow obstruction and decreased gastrointestinal motility because of the risk of urinary retention.